drugset
drugset / Trial / NCT05688839

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

NCT05688839 ↗

Phase 2 Unknown 60 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, placebo parallel control study and is expected to enroll 20-60 eligible patients with severe novel coronavirus pneumonia.

Timeline

Start
2024-04
Primary completion
2025-02
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 100 mg —

Indications

COVID-19